328 related articles for article (PubMed ID: 36131561)
1. Emerging tyrosine kinase inhibitors for head and neck cancer.
Long Z; Grandis JR; Johnson DE
Expert Opin Emerg Drugs; 2022 Sep; 27(3):333-344. PubMed ID: 36131561
[TBL] [Abstract][Full Text] [Related]
2. Investigational multitargeted kinase inhibitors in development for head and neck neoplasms.
Sola AM; Johnson DE; Grandis JR
Expert Opin Investig Drugs; 2019 Apr; 28(4):351-363. PubMed ID: 30753792
[TBL] [Abstract][Full Text] [Related]
3. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
[TBL] [Abstract][Full Text] [Related]
4. An update: emerging drugs to treat squamous cell carcinomas of the head and neck.
Lee YS; Johnson DE; Grandis JR
Expert Opin Emerg Drugs; 2018 Dec; 23(4):283-299. PubMed ID: 30376740
[No Abstract] [Full Text] [Related]
5. Emerging drugs for head and neck cancer.
Wen Y; Grandis JR
Expert Opin Emerg Drugs; 2015 Jun; 20(2):313-29. PubMed ID: 25826749
[TBL] [Abstract][Full Text] [Related]
6. Emerging immune checkpoint inhibitors for the treatment of head and neck cancers.
Green SE; McCusker MG; Mehra R
Expert Opin Emerg Drugs; 2020 Dec; 25(4):501-514. PubMed ID: 33196319
[No Abstract] [Full Text] [Related]
7. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
Cohen RB
Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
[TBL] [Abstract][Full Text] [Related]
8. Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update.
Bhatia A; Burtness B
Drugs; 2023 Feb; 83(3):217-248. PubMed ID: 36645621
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab for the treatment of head and neck squamous cell cancer.
Ho WJ; Mehra R
Expert Opin Biol Ther; 2019 Sep; 19(9):879-885. PubMed ID: 31317798
[No Abstract] [Full Text] [Related]
10. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
11. [FGFR-targeted therapy in head and neck carcinomas].
Dietrich D
HNO; 2021 Mar; 69(3):172-184. PubMed ID: 32519203
[TBL] [Abstract][Full Text] [Related]
12. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
[TBL] [Abstract][Full Text] [Related]
13. Current State and Future Directions of EGFR-Directed Therapy in Head and Neck Cancer.
Tathineni P; Joshi N; Jelinek MJ
Curr Treat Options Oncol; 2023 Jun; 24(6):680-692. PubMed ID: 37067660
[TBL] [Abstract][Full Text] [Related]
14. Current Role of Dacomitinib in Head and Neck Cancer.
Elicin O; Ozsahin M
Expert Opin Investig Drugs; 2016 Jun; 25(6):735-42. PubMed ID: 27070370
[TBL] [Abstract][Full Text] [Related]
15. Head and neck squamous cell carcinoma: Exploring frontiers of combinatorial approaches with tyrosine kinase inhibitors and immune checkpoint therapy.
Scarini JF; Lavareze L; de Lima-Souza RA; Emerick C; Gonçalves MT; Figueiredo-Maciel T; Vieira GS; Kimura TC; de Sá RS; Aquino IG; Fernandes PM; Kowalski LP; Altemani A; Mariano FV; Egal ESA
Crit Rev Oncol Hematol; 2022 Dec; 180():103863. PubMed ID: 36334881
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of head and neck squamous cell carcinoma (HNSCC). Immune checkpoint blockade.
Przybylski K; Majchrzak E; Weselik L; Golusiński W
Otolaryngol Pol; 2018 Sep; 72(6):10-16. PubMed ID: 30647199
[TBL] [Abstract][Full Text] [Related]
17. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
[TBL] [Abstract][Full Text] [Related]
18. EGFR tyrosine kinase inhibitors differentially affect autophagy in head and neck squamous cell carcinoma.
Cai J; Sun M; Ge X; Sun Y
Biochem Biophys Res Commun; 2017 May; 486(4):1027-1033. PubMed ID: 28366635
[TBL] [Abstract][Full Text] [Related]
19. EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.
Nelhűbel GA; Cserepes M; Szabó B; Türk D; Kárpáti A; Kenessey I; Rásó E; Barbai T; Hegedűs Z; László V; Szokol B; Dobos J; Őrfi L; Tóvári J
Pathol Oncol Res; 2021; 27():620256. PubMed ID: 34257586
[No Abstract] [Full Text] [Related]
20. Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer.
Bhola NE; Freilino ML; Joyce SC; Sen M; Thomas SM; Sahu A; Cassell A; Chen CS; Grandis JR
Mol Cancer Ther; 2012 Jun; 11(6):1236-46. PubMed ID: 22491800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]